Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cell & Gene Therapy Asia 2019

Asuka Morizane's Biography



Asuka Morizane, Assistant Professor, Center for iPS Cell Research and Application (CiRA), Kyoto University

Asuka Morizane received his M.D. in 1996 from Tokyo Medical and Dental University, and his Ph.D. in 2004 from Kyoto University. After working as a neurosurgeon in Kobe City General Hospital, he moved to Lund University, Sweden, where he researched on the cell therapy for Parkinson’s disease with human embryonic stem cells. He returned to Kyoto University in2008 and started the research with iPSCs. He was appointed as an assistant professor at the center for iPS Cell Research and Application (CiRA), Kyoto University since 2012. Over the last 15 years, he has focused on the application of stem cells for Parkinson’s disease. Recently he used mainly human iPS cells as donor cells. He and his colleagues have performed in vitro and in vivo (especially with monkeys) experiments for clinical application. The group showed the functional recovery of MPTP-treated monkeys after transplantation of clinically compatible human iPS cell-derived dopamine neural progenitors without any tumorigenesis. Based on those research results, the group started the clinical trial of the cell therapy for Parkinson’s disease with iPS cells from 2018.

Asuka Morizane Image

Clinical Application of iPS Cell Therapy For Parkinson’s Disease

Monday, 11 November 2019 at 14:10

Add to Calendar ▼2019-11-11 14:10:002019-11-11 15:10:00Europe/LondonClinical Application of iPS Cell Therapy For Parkinson’s DiseaseCell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com

The innovation of induced pluripotent stem cells (iPSCs) and previous embryonic stem cell (ESC) technologies are drawing attention to their application for regenerative medicine. Parkinson’s disease (PD) is one of the most promising target diseases based on the history of fetal nigral transplantation in clinics. The technology of iPSCs offers a limitless and more advantageous donor source than aborted tissue. One of the advantages is possibility of preparing immunologically compatible donor cells from self-derived or allogeneic iPSCs. We have successfully established a protocol for donor induction with clinically compatible grade and have transplanted these neurons into PD models of mice, rats, and cynomolgus monkeys as preclinical studies. Based on these research results, the clinical trial of cell therapy for PD with iPS cells started since 2018. The presentation will include the recent research results and the proceedings of the clinical trial.


Add to Calendar ▼2019-11-11 00:00:002019-11-12 00:00:00Europe/LondonCell and Gene Therapy Asia 2019Cell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com